<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11117DED-1FA6-4714-A680-FB438063C627"><gtr:id>11117DED-1FA6-4714-A680-FB438063C627</gtr:id><gtr:name>Multimedica Research Hospital Milan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Bristol Heart Institute</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11117DED-1FA6-4714-A680-FB438063C627"><gtr:id>11117DED-1FA6-4714-A680-FB438063C627</gtr:id><gtr:name>Multimedica Research Hospital Milan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5ACB5C11-9B05-4384-A43B-BB35454ACDA9"><gtr:id>5ACB5C11-9B05-4384-A43B-BB35454ACDA9</gtr:id><gtr:firstName>Costanza</gtr:firstName><gtr:surname>Emanueli</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901764"><gtr:id>C494F6D5-3D4B-43EB-ABD3-9824520AECE9</gtr:id><gtr:title>Role of miRNA-503 in diabetes-induced impairment of post-ischaemic neovascularisation in limb muscles</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901764</gtr:grantReference><gtr:abstractText>A high number of diabetic patients develop critical restriction in the blood supply to the legs as a result of a major artery becoming blocked, resulting in the skeletal muscles being starved of oxygen. The condition is characterized by pain at rest and/or established sores that endanger the integrity and function of the legs. No effective drug is available to treat the condition, and reopening the blocked artery by surgery is often unfeasible or is unsuccessful. This means that the outcome for patients remains very poor, and the condition frequently leads to foot amputation. Even this course of action is associated with a high death rate, with 5 to 20% of patients dying early after surgery, and of those who survive, only 60% survive beyond 2 years. A second amputation is required in 30% of cases. A diabetic patient is more susceptible to progression of this condition because the growth and development of new blood vessels around and below a blocked artery is impaired. The research we propose aims to help the development of new blood vessels, which could delay progression of the condition and help save the patient?s life. This therapeutic strategy is now a possibility following the discovery of vascular growth factors that stimulate the growth of blood vessels. Scientists have also recently discovered that in diabetes the production of these vascular growth factors can be inhibited. We propose that this inhibition occurs due to a wrong signal from a newly discovered class of molecules called microRNAs, which regulate expression of our genes and thus control protein production. Each microRNA influences the production of several proteins, so a single microRNA could suffice to create major health problems. We know that diabetes can lead to the overproduction of microRNA-503, and that an excess of this leads to poor development of blood vessels. We propose to show that by inhibiting the action of microRNA-503 in vascular cells exposed to high glucose, mimicking the diabetic condition, the status of blood vessels is improved. This research could lead to the development of new therapeutic treatments for use in diabetes.</gtr:abstractText><gtr:technicalSummary>When an ischaemic event occurs as a consequence of blockage of an artery by clots, the organism reacts by mounting a neovascularization response aiming at restoring blood perfusion. This reparative response is remarkably compromised by diabetes mellitus, due to the concomitant impairment of collateral remodelling and microvascular angiogenesis, which accounts for the poor clinical outcome of diabetic patients with ischaemic complications. Remedies to prevent and treat diabetic macro/microvascular complications are urgently needed. 
MicroRNAs (miRNAs) are small noncoding RNAs, which mediate either translational arrest or degradation of targeted mRNA transcripts through imperfect base pairing with their 3?-UTR (untranslated regions). miRNAs are emerging as important regulators of gene expression. The pathogenic role of miRNAs has been described in cancer and cardiovascular diseases and miRNAs are currently at the forefront of biomedical research. 
We hypothesize that dysregulation of miRNA expression in microvascular endothelial cells (ECs) is responsible for diabetes-induced defective angiogenesis. In particular, this project will focus on microRNA-503 (miR-503), which is over-expressed in diabetic ECs. Bioinformatics analyses predict that genes controlling cell cycle and angiogenesis are potential targets for miR-503. Moreover, pilot data showed that miR-503 over-expression impairs EC proliferation and in vitro angiogenesis, while miR-503 inhibition normalizes ECs proliferation in culture conditions which mimic diabetes.
This proposal aims to demonstrate that miR-503 is a key player in and a potential therapeutic target for diabetes-induced impairment of post-ischaemic reparative neovascularization. Specifically, we propose to employ and compare two strategies, e.g. systemic administration of single-stranded RNA oligonucleotides complementary to miR-503 ?antagomir- and a novel gene therapy approach based on the adenovirus-mediated local delivery of a 3?UTR decoy miR-503, to down-regulate miR-503 in diabetic and ischaemic murine muscles.
We additionally propose to validate the target genes that mediate the deleterious effects of miR-503 on ECs. 
The ultimate goal of our research is to improve the understanding of the molecular changes underpinning the damaging action of hyperglycaemia on ECs and exploit the new knowledge to cure diabetes-induced ischaemic complications. To the best of our knowledge, this innovative project is the first to elucidate the importance of a miRNA in the context of diabetic endotheliopathy, thus posing the cornerstone for the exploitation of miRNAs as drugable targets for the treatment of vascular complications of diabetes.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>241439</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>BHF Glasgow Cardiovascular Research Centre</gtr:department><gtr:description>miRNAs in ESC differentiating into endothelial cells</gtr:description><gtr:id>DD2BAABE-634A-43D9-94B4-B3C51EB0AD9C</gtr:id><gtr:impact>Joint paper:

Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo.

Kane NM, Meloni M, Spencer HL, Craig MA, Strehl R, Milligan G, Houslay MD, Mountford JC, Emanueli C, Baker AH.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1389-97. Epub 2010 Apr 29.

PMID: 20431067 

Awarded special project grant with British Heart Foundation to study ESC-EC protocols and test for efficacly in models of limb ischemia.

Pending MRC outline for TSCCR grant</gtr:impact><gtr:outcomeId>MfmFTUgwZwA-1</gtr:outcomeId><gtr:partnerContribution>We are working together at understanding the regenerative properties of ESC-ECs (engineered or not to modulate miRNA expression) in mouse models of limb ischemia.</gtr:partnerContribution><gtr:piContribution>We supply our expertise in animal models of ischemia and miRNAs</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Bioengineering</gtr:department><gtr:description>omics and bioinformatics</gtr:description><gtr:id>06B12B46-B920-439B-A936-FED895FFDF54</gtr:id><gtr:impact>paper and grant</gtr:impact><gtr:outcomeId>58bd5ba51807c0.86829979-1</gtr:outcomeId><gtr:partnerContribution>computational analyses</gtr:partnerContribution><gtr:piContribution>Petretto is coPI in my BHF programme grany</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences</gtr:department><gtr:description>miRNAs in adult progenitor cells</gtr:description><gtr:id>0CE99A28-85EA-40A5-9441-B92AD14C2AE8</gtr:id><gtr:impact>we have published a joint paper:

Transplantation of Human Pericyte Progenitor Cells Improves the Repair of Infarcted Heart Through Activation of an Angiogenic Program Involving Micro-RNA-132.

Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, Fortunato O, Avolio E, Cesselli D, Beltrami AP, Angelini G, Emanueli C, Madeddu P.

Circ Res. 2011 Sep 30;109(8):894-906. Epub 2011 Aug 25.

PMID: 218686951868695

We have applied and on a MRC-TSCR together and a MRC programme grant is pending.</gtr:impact><gtr:outcomeId>krFBWytn6zB-1</gtr:outcomeId><gtr:partnerContribution>We have together elucidated the actions of miR-132 in pericytes</gtr:partnerContribution><gtr:piContribution>we have helped them to set up methods to investigated miRNA expression and functions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Multimedica Research Hospital Milan</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>collaboration with Multimedica Research hospital (Milan) to study microRNAs in samples from diabetic patients with critical limb ischaemia</gtr:description><gtr:id>9785BC9C-B2E9-46A8-B262-BA79507F7578</gtr:id><gtr:impact>Increase in knowledge and Publications
We have ethics to receive their samples and work on them</gtr:impact><gtr:outcomeId>54b530395ad230.87961970-1</gtr:outcomeId><gtr:partnerContribution>clinical samples</gtr:partnerContribution><gtr:piContribution>microRNA expertise</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre of Vascular Regenerative Medicine</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RM/13/2/ 30158</gtr:fundingRef><gtr:id>65753EA4-C237-4241-8FD9-89A52D297521</gtr:id><gtr:outcomeId>58c7dbfae1cb49.35974369</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100040</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fellowship BHF PhD studentship</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/10/61/28566</gtr:fundingRef><gtr:id>F572A36F-643F-42D8-AD7B-C6936633F90F</gtr:id><gtr:outcomeId>58c7ee18272f68.67699107</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>164704</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - Investigation on microRNA-24 as a novel therapeutic target in limb ischaemia associated with diabetes</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:fundingRef>11/0004194</gtr:fundingRef><gtr:id>B1E8C23F-0F4A-430D-9DB1-454696EFF242</gtr:id><gtr:outcomeId>GCN1mzcwcq8</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:country>Burkina Faso</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>MEDIRAD: Implications of Medical Low Dose Radiation Exposure European Community</gtr:description><gtr:end>2021-07-02</gtr:end><gtr:fundingOrg>National Centre for Research and Training on Malaria (CNRFP)</gtr:fundingOrg><gtr:id>B7C85E3D-8EB4-4ABC-8BA0-FB79D41F1F1C</gtr:id><gtr:outcomeId>58c7e1fdead5d8.44061693</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>806028</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2020-05-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/15/5/31446</gtr:fundingRef><gtr:id>810AC536-3D6E-4C8C-9AB1-59D4A31B3DD7</gtr:id><gtr:outcomeId>58c7eab4545b56.17002950</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>73656</gtr:amountPounds><gtr:country>New Zealand</gtr:country><gtr:currCode>NZD</gtr:currCode><gtr:currCountryCode>New Zealand</gtr:currCountryCode><gtr:currLang>en_NZ</gtr:currLang><gtr:description>Novel microRNA based therapy for regeneration of diabetic heart</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Royal Society of New Zealand</gtr:fundingOrg><gtr:fundingRef>16-UOO-006-CSG</gtr:fundingRef><gtr:id>6ABED670-DB39-44EE-AA71-64E4D694CB7C</gtr:id><gtr:outcomeId>58c6a820d65532.91971833</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>420000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Intermediate Basic Science Research Fellowship for Andrea Caporali (under my supervision) - Inter-cellular trafficking and regulation of microRNA-503 expression in diabetes induced microvascular complications</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/11/52/29018</gtr:fundingRef><gtr:id>7EA57F6E-453A-4D5D-88DC-10555251D883</gtr:id><gtr:outcomeId>BUd3U1eQPxG0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Leducq Trans-Atlantic Network and Training Programme : MicroRNA-Based Therapeutic Strategies in Vascular Disease</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>The Leducq Foundation (Fondation Leducq)</gtr:fundingOrg><gtr:fundingRef>13 CVD 02</gtr:fundingRef><gtr:id>028B2298-105F-4780-9DFC-BD7EFFDB7687</gtr:id><gtr:outcomeId>58c7ddcd89a141.46046302</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>564864</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fellowship</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/10/001/27959</gtr:fundingRef><gtr:id>1A7F9729-6A2C-483A-A3E0-CB0BDF84CAC8</gtr:id><gtr:outcomeId>58c7ed05dfb762.77227715</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>decoy for miR-503 as a plasmid and as an adenovirus</gtr:description><gtr:id>A5258799-BCDB-45B2-961F-EFD68047032C</gtr:id><gtr:impact>this is a good tool to manipulate miR-503 activity in vitro and in vivo.</gtr:impact><gtr:outcomeId>qMMPxr7bBkg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>decoy for miR-503 as a plasmid and as an adenovirus</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D8BB9000-7E28-49DC-ACB1-E106C273E42C</gtr:id><gtr:title>Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>W9dgB4H98CS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F906258-1741-40A2-9D2D-DEC281CC3B86</gtr:id><gtr:title>MicroRNA-503 and the extended microRNA-16 family in angiogenesis.</gtr:title><gtr:parentPublicationTitle>Trends in cardiovascular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1050-1738</gtr:issn><gtr:outcomeId>pm_13316_26_22814423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9127694B-0831-4031-BD91-077ED322E692</gtr:id><gtr:title>Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>pm_13316_26_23065828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>252C0D1D-B416-4B4A-9BD7-E677C76796FC</gtr:id><gtr:title>MicroRNAs in Postischemic Vascular Repair.</gtr:title><gtr:parentPublicationTitle>Cardiology research and practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2090-0597</gtr:issn><gtr:outcomeId>pm_13316_26_22482069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BD4D627-1291-4231-BC1A-C370814A2CAC</gtr:id><gtr:title>Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/272d0d63dabd429db6c30970fcf5a89a"><gtr:id>272d0d63dabd429db6c30970fcf5a89a</gtr:id><gtr:otherNames>Kane NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>pm_13316_26_22232059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>017866B4-4B3F-42A0-AB30-D262603E33EA</gtr:id><gtr:title>Role of microRNAs in diabetes and its cardiovascular complications.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e95301cac93b472e4a0152d9a300ac0a"><gtr:id>e95301cac93b472e4a0152d9a300ac0a</gtr:id><gtr:otherNames>Shantikumar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>pm_13316_26_22065734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B13E0BE-F8B2-4717-B88A-E8F292ECA0E4</gtr:id><gtr:title>MicroRNA regulation in angiogenesis.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>pm_13316_26_21777698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B02F8EF-FF5D-4780-A55C-E21B3F23B386</gtr:id><gtr:title>MicroRNA transport in cardiovascular complication of diabetes.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56d99ee5063062.79341915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A237A9AC-A145-4414-AE7B-6A1701B8EBE2</gtr:id><gtr:title>p75(NTR)-dependent activation of NF-?B regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99da213432b1e01683836c12d49541ef"><gtr:id>99da213432b1e01683836c12d49541ef</gtr:id><gtr:otherNames>Caporali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d9a5e0b2e275.00530092</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901764</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>